Riskpilot← Back to searchSign inGet full accessGram Scientific ApS
APSActiveCVR 43122193Aage Grams Vej 1Manufacture of non-domestic air conditioning equipment · NACE 2825Est. 2022164 employees
Revenue 2025
DKK 61,7M
-18% vs 2024
EBITDA margin
6.3%
-80% vs 2024
Equity ratio
61.0%
Financial strength
Net profit 2025
DKK 2,6M
-82% vs 2024
| Revenue | DKK 61,7M | -18% |
| EBITDA | DKK 3,9M | -80% |
| Net profit | DKK 2,6M | -82% |
| Total assets | DKK 77,9M | +6% |
| Equity | DKK 47,6M | -1% |
| Employees | 164 | — |
Legal name
Gram Scientific ApS
CVR number
43122193
Legal form
Anpartsselskab
NACE code
2825 · Manufacture of non-domestic air conditioning equipment
Founded
14. marts 2022
Share capital
DKK 800.000
Employees
164 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af 2 direktører i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er udvikling, produktion og distribution af BTB produkter samt anden hermed forbundet virksomhed efter bestyrelsens skøn.
Address
Aage Grams Vej 1
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | 50.170 | 75.065 | 61.673 |
| Staff expenses | -0 | -50.914 | -55.728 | -57.781 |
| EBITDA | 0 | 42.253 | 19.336 | 3.892 |
| Depreciation & amort. | -0 | -0 | -104 | -294 |
| EBIT | 0 | 42.253 | 19.232 | 3.598 |
| Net financials | -2 | 270 | -22 | -231 |
| Profit before tax | -2 | 42.523 | 19.210 | 3.367 |
| Tax | -0 | 9.398 | 4.373 | 770 |
| Net profit | -2 | 33.125 | 14.837 | 2.597 |
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 98 | 69.512 | 73.775 | 77.941 |
| Equity | 98 | 41.123 | 47.960 | 47.556 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 24.051 | 22.570 | 26.694 |
| Total debt | 0 | 24.051 | 22.570 | 26.694 |
EBITDA margin
6.3%
This company
15.8%
Market median
-60% vs market
20222025
Equity ratio
61.0%
This company
38.2%
Market median
+60% vs market
20222025
Return on equity
5.5%
This company
18.4%
Market median
-70% vs market
20222025
Net profit margin
4.2%
This company
8.1%
Market median
-48% vs market
20222025
Asset turnover
0.79×
This company
1.12×
Market median
-29% vs market
20222025
Debt / equity
0.64×
This company
0.62×
Market median
+3% vs market
20222025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-03-14 – 2022-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HG Management | Management | 2023 | — | — |
HN Management | Management | 2022 | — | — |
OB Management | Management | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
BLH Invest 1 ApS | Company | 33.3% | 50.0% | 2023 |
HAADE INVEST ApS | Company | 20.0% | 20.0% | 2023 |
Invest 75 ApS | Company | 20.0% | 20.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
HAADE INVEST ApS
Gram Scientific ApS Board members of Gram Scientific ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Henrik Gammelager Kristensen | Management | 0 companies |
| Henrik Nørgaard | Management | 0 companies |
| Ole Brandorff-Lund | Management | 0 companies |
| Anders Sjøgaard | Chairman | 0 companies |